SEARCH

SEARCH BY CITATION

References

  • Abels, R.I. (1992) Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Seminars in Oncology, 19, 2935.
  • Barlogie, B. & Beck, T. (1993) Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells, 11, 8894.
  • Beguin, Y. (1998) Prediction of response to treatment with recombinant human erythropoietin in anemia associated with cancer. Medical Oncology, 15, 3846s.
  • Casadevall, N. (1998) Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes. Seminars in Oncology, 25, 1218.
  • Cazzola, M., Messinger, D., Battistel, V., Bron, D., Cimino, R., Enller-Ziegler, L., Essers, U., Greil, R., Grossi, A., Jäger, G., LeMevel, A., Najman, A., Silingardi, V., Spriano, M., Van Hoof, A. & Ehmer, B. (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood, 86, 44464453.
  • Cazzola, M., Ponchio, L., Pedrotti, C., Farina, G., Cerani, P., Lucotti, C., Novella, A., Rovati, A., Bergamaschi, G. & Beguin, Y. (1996) Prediction of response to recombinant human erythropoietin (rHuEPO) in anemia of malignancy. Haematologica, 81, 434441.
  • Coiffier, B. (2000) The impact and management of anaemia in haematological malignancies. Medical Oncology, 17, 210s.
  • Dammacco, F., Silvestris, F., Castoldi, G.L., Grassi, B., Bernasconi, C., Nadali, G., Perona, G., De Laurenzi, A., Torelli, U., Ascari, E., Rossi Ferrini, P.L., Caligaris-Cappio, F., Pileri, A. & Resegotti, L. (1998) The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. International Journal of Clinical and Laboratory Research, 28, 127134.
  • Dammacco, F., Castoldi, G. & Rödjer, S. (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. British Journal of Haematology, 113, 172179.
  • Demetri, G.D., Kris, M., Wade, J., Degos, L., Cella, D. & Procrit Study Group (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Journal of Clinical Oncology, 16, 34123425.
  • Draper, N.R. & Smith, H. (1981) Orthogonal polynomials. In: Applied Regression Analysis 2nd edn. pp. 266274. John Wiley & Sons, New York.
  • Egrie, J.C. & Browne, J.K. (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer, 84, 310.
  • Faquin, W.C., Schneider, T.J. & Goldberg, M.A. (1992) Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood, 79, 19871994.
  • Gabrilove, J.L., Cleeland, C.S., Livingston, R.B., Sarokhan, B., Winer, E. & Einhorn, L.H. (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology, 19, 28752882.
  • Garton, J.P., Gertz, M.A., Witzig, T.E., Greipp, P.R., Lust, J.A., Schroeder, G. & Kyle, R.A. (1995) Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Archives of Internal Medicine, 155, 20692074.
  • Glaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tchekmedyian, S., Vadhan-Raj, S. & Procrit Study Group (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Journal of Clinical Oncology, 15, 12181234.
  • Glaspy, J., Colowick, A.B., Heatherington, A. & NESP Oncology Study Group (2000) Novel erythropoiesis stimulating protein (NESP) exhibits a prolonged serum half-life (t1/2) in oncology patients (pts). Proceedings of ASCO, 19, 54a.
  • Glaspy, J., Jadeja, J., Justice, G., Kessler, J., Richards, D., Schwarzberg, L., O'Byrne, J., Armstrong, S. & Colowick, A. (2001) Randomized, active-controlled, phase 1/2, dose-escalation study of NESP administered weekly and every 2 weeks in patients with solid tumors. Proceedings of ASCO, 20, 387a.
  • Groopman, J.E. & Itri, L.M. (1999) Chemotherapy-induced anemia in adults: incidence and treatment. Journal of the National Cancer Institute, 91, 16161634.
  • Heatherington, A.C., Schuller, J. & Mercer, A.J. (2001) Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. British Journal of Cancer, 84, 1116.
  • Kotasek, D., ARANESP 980291 Study Group, Berg, R., Poulsen, E. & Colowick, A. (2000) Randomized, double-blind, placebo-controlled, phase I/II dose finding study of ARANESP™ administered once every 3 weeks in solid tumor patients. Blood, 96, 1268.
  • Littlewood, T.J., Bajetta, E., Nortier, J.W.R., Vercammen, E., Rapoport, B. & Epoetin Alfa Study Group. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 28652874.
  • Ludwig, H., Fritz, E., Kotzmann, H., Höcker, P., Gisslinger, H. & Barnas, U. (1990) Erythropoietin treatment of anemia associated with multiple myeloma. New England Journal of Medicine, 322, 16931699.
  • Ludwig, H., Pecherstorfer, M., Leitgeb, C. & Fritz, E. (1993) Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells, 11, 348355.
  • Ludwig, H., Fritz, E., Leitgeb, C., Pecherstorfer, M., Samonigg, H. & Schuster, J. (1994) Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood, 84, 10561063.
  • Macdougall, I.C. (2000) Novel erythropoiesis stimulating protein. Seminars in Nephrology, 20, 375381.
  • Macdougall, I.C., Gray, S.J., Elston, O., Breen, C., Jenkins, B., Browne, J. & Egrie, J. (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with Epoetin alfa in dialysis patients. Journal of the American Society of Nephrology, 10, 23922395.
  • Mittelman, M., Zeidman, A., Fradin, Z., Magazanik, A., Lewinski, U.H. & Cohen, A. (1997) Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematologica, 98, 204210.
  • Moliterno, A.R. & Spivak, J.L. (1996) Anemia of cancer. Hematology/Oncology Clinics of North America, 10, 345363.
  • Nowrousian, M.R. (1998) Recombinant human erythropoietin (rHuEPO) in the prevention and treatment of chemotherapy-induced anaemia. Medical Oncology, 15, 141144.
  • Österborg, A. (2000) The role of recombinant human erythropoietin in the management of anemic cancer patients: focus on haematological malignancies. Medical Oncology, 17, 1722s.
  • Österborg, A., Boogaerts, M.A., Cimino, R., Essers, U., Holowiecki, J., Juliusson, G., Jäger, G., Najman, A., Peest, D. & European Study Group of Erythropoietin (Epoetin beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma – a randomized multicenter study. Blood, 87, 26752682.
  • Österborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M. & Messinger, D.for the Epoetin Beta Hematology Study Group (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematolic malignancies. Journal of Clinical Oncology, 20, 24862494.
  • Pirker, R., Vansteenkiste, J., Gateley, J., Yates, P., Colowick, A., Musil, J. & NESP 980297 Study Group (2001) A phase 3, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer. Proceedings of ASCO, 20, 394a.
  • Silvestris, F., Romito, A., Fanelli, P., Vacca, A. & Dammacco, F. (1995) Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Annals of Hematology, 70, 313318.